AOD

What AOD is

AOD-9604 is a synthetic peptide corresponding to amino acids 176–191 of human growth hormone (hGH), with an additional N-terminal tyrosine residue added for molecular stabilisation ^[1][2]. The name 'AOD' stands for 'Anti-Obesity Drug', reflecting the original therapeutic intent behind its development. The compound was pioneered by Professor Frank Ng and colleagues at Monash University (Australia) in the 1990s, working in collaboration with Metabolic Pharmaceuticals Ltd, with the explicit goal of isolating the fat-metabolising activity of GH from its anabolic, growth-promoting, and diabetogenic effects ^[3][4].

As a compound class, AOD-9604 belongs to the category of peptide GH fragments—short synthetic analogues of naturally occurring sequences within the full GH protein. A key early observation driving its development was that the C-terminal region of hGH appeared to account for the hormone's lipolytic activity independently of receptor-level IGF-1 stimulation: clinical trial data confirmed that AOD-9604 did not elevate plasma IGF-1, a finding described at the time as 'particularly surprising' given the long-held assumption that hGH effects are modulated through IGF-1 secretion ^[5]. Over roughly a decade, more than USD 50 million was invested in taking the compound through six human clinical trials ^[3][6], before pharmaceutical development for the obesity indication was discontinued around 2007 following an inconclusive Phase IIb result ^[6].

What it is being researched for

1. Adipose tissue lipolysis and fat metabolism

The primary and most extensively documented research area for AOD-9604 is its capacity to stimulate lipolysis—the enzymatic hydrolysis of stored triglycerides into free fatty acids and glycerol—in adipocyte cell populations ^[1][7]. Preclinical work conducted at Monash University demonstrated that chronic administration of AOD-9604 to genetically obese (ob/ob) mice and Zucker rats produced significant reductions in body-weight gain and increases in in-vivo fat oxidation comparable to those seen with full-length hGH, while leaving glucose homeostasis intact ^[2][7]. A complementary anti-lipogenic effect has also been proposed: researchers hypothesised that AOD-9604 may inhibit acetyl-CoA carboxylase, an enzyme involved in de novo fatty-acid synthesis, potentially shifting the metabolic balance toward net fat mobilisation rather than fat storage ^[8]. These dual actions—promoting breakdown while attenuating new formation—form the conceptual basis for its continued study in obesity and body-composition research, even though the human trial data have been less clear-cut ^[6].

2. Obesity pharmacology and clinical weight management

AOD-9604 completed six human clinical trials between approximately 2001 and 2007, making it one of the few research peptides to accumulate a substantial human safety dataset ^[3][6]. An early Phase IIa randomised trial reported that subjects receiving AOD-9604 lost an average of approximately 2.6 kg versus 0.8 kg in the placebo group over 12 weeks ^[9]. However, the pivotal Phase IIb study—a 24-week trial enrolling 536 participants—did not achieve statistical significance for weight loss at any tested concentration versus placebo ^[6][10]. Both the U.S. FDA (which later classified AOD-9604 as a Category 2 bulk drug substance with compounding restricted pending further review) and Australia's Therapeutic Goods Administration rejected obesity indications following the Phase IIb outcome ^[10]. Separately, AOD-9604 obtained U.S. GRAS (Generally Recognized As Safe) status for use as a food ingredient—a limited food-safety designation categorically distinct from drug approval for any medical indication ^[4][11].

3. Cartilage regeneration and osteoarthritis

A secondary research direction emerged from observations that AOD-9604 may influence musculoskeletal tissue beyond adipose cells. In vitro studies reported that the peptide promotes chondrocyte proliferation and proteoglycan synthesis, including increased production of type II collagen and aggrecan—the primary structural components of articular cartilage matrix ^[12]. A 2015 study published in Annals of Clinical and Laboratory Science investigated AOD-9604 in a collagenase-induced knee osteoarthritis rabbit model; intra-articular application, particularly in combination with hyaluronic acid, was associated with enhanced cartilage regeneration and reduced joint degradation compared to controls ^[8][12]. Animal models of osteoarthritis have also documented reduced cartilage degradation scores and decreased inflammatory markers ^[12]. Importantly, no randomised human trial examining AOD-9604 for osteoarthritis or any orthopaedic indication has been published as of 2026, and the existing cartilage data are best interpreted as hypothesis-generating preclinical evidence ^[10].

4. Metabolic safety profile and glucose homeostasis

One of the most reproducible findings across both animal and human studies of AOD-9604 is an absence of the adverse metabolic effects typically associated with exogenous GH administration. Competition binding assays showed that AOD-9604 does not compete with hGH for binding at the GH receptor ^[9], and cell-proliferation assays confirmed it does not induce IGF-1-dependent cell growth even at elevated concentrations ^[9]. Chronic administration to obese mice produced no changes in circulating plasma glucose or insulin sensitivity, in contrast to full-length hGH, which depressed glucose oxidation and elevated plasma glucose in the same model ^[9]. Across 893 human subjects across all six clinical trials, researchers documented zero treatment-related serious adverse events, zero treatment withdrawals, zero antibody formation, and no clinically significant changes in IGF-1 or glucose parameters ^[3]. This safety profile has maintained scientific interest in the peptide as a research tool for disentangling GH's metabolic actions.

5. Beta-3 adrenergic receptor biology

AOD-9604's mechanism has been studied as a window into the beta-3 adrenergic receptor (β3-AR) pathway, the principal lipolytic signalling axis in white adipose tissue ^[7][13]. In obese murine models—where β3-AR expression is typically suppressed relative to lean animals—AOD-9604 treatment appeared to restore β3-AR mRNA levels toward those seen in lean controls, coinciding with increased lipolytic activity ^[7][13]. Knockout experiments provided mechanistic nuance: in β3-AR-deficient mice, chronic AOD-9604 treatment failed to reduce body weight, yet acute exposure still increased energy expenditure and fat oxidation, leading investigators to conclude that the peptide's lipolytic actions are not mediated *directly* through β3-AR but may involve additional, incompletely characterised pathways ^[7]. This finding underscores how AOD-9604 continues to serve as a useful research probe for understanding adrenergic control of adipocyte metabolism ^[13].

6. Bone metabolism

Patent literature and early mechanistic studies noted that further work on AOD-9604 and related C-terminal GH fragments indicated an effect on bone metabolism, specifically increased osteoblast formation without a corresponding increase in osteoclast formation ^[5]. This observation suggested a potential anabolic bone signal that is distinct from both the peptide's lipolytic mechanism and classical IGF-1-dependent GH bone pathways ^[5]. To date, the bone-metabolism findings remain at the level of preclinical observation and patent disclosures; no peer-reviewed clinical trial in human subjects has been published examining AOD-9604 for bone-density or osteogenic outcomes.

How it is thought to work

AOD-9604 is thought to exert its primary metabolic effects through direct action on adipocytes rather than through the classical GH receptor/JAK2/STAT5 signalling pathway activated by full-length human growth hormone ^[2][7]. Competition binding assays confirmed that the peptide does not compete with hGH for the GH receptor, and sensitive cell-proliferation assays showed it does not activate IGF-1-dependent growth signalling ^[9]. Instead, researchers have proposed a dual-pathway model: acutely, AOD-9604 appears to stimulate lipolysis and increase energy expenditure through receptor-independent or incompletely characterised pathways; chronically, it has been observed to upregulate the expression of beta-3 adrenergic receptor (β3-AR) mRNA in white adipocytes of obese animals, potentially restoring the blunted lipolytic responsiveness of obese fat cells to catecholamine signals ^[7][13]. The importance of the β3-AR pathway to the compound's chronic weight-reducing effects was demonstrated in knockout studies where β3-AR-deficient mice did not exhibit body-weight reduction following repeated AOD-9604 treatment ^[7].

At the enzymatic level, AOD-9604-associated lipolysis appears linked to activation of hormone-sensitive lipase (HSL), the rate-limiting enzyme for hydrolysis of stored triglycerides into free fatty acids and glycerol ^[8]. Elevated glycerol release in treated adipocyte preparations has been used as a biochemical marker of this lipid-breakdown activity ^[8]. An additional anti-lipogenic effect has been proposed via putative inhibition of acetyl-CoA carboxylase, which would suppress de novo fatty-acid synthesis ^[8]. In the context of cartilage, a separate and mechanistically distinct pathway has been hypothesised involving direct effects on chondrocyte growth factor receptors and matrix metalloproteinase activity regulation, though this remains poorly characterised ^[12]. Across all proposed pathways, the absence of IGF-1 elevation and glucose dysregulation is a consistent finding, distinguishing AOD-9604's metabolic fingerprint from that of full GH ^[5][9].

Where the evidence stands

The evidence base for AOD-9604 spans three tiers of increasing clinical weight. At the cell and tissue level, in vitro experiments demonstrated lipolytic activity when adipose tissue from genetically obese (ob/ob) mice was incubated with AOD-9604 preparations, with lipolysis confirmed by glycerol release ^[7]. In rodent models, chronic treatment reduced body-weight gain and adipose tissue mass in obese mice and Zucker rats, increased in-vivo fat oxidation, and restored suppressed β3-AR mRNA expression to lean-equivalent levels—all without perturbing glucose or IGF-1 ^[2][7][9]. A 2015 rabbit osteoarthritis study found that intra-articular AOD-9604, especially combined with hyaluronic acid, improved cartilage regeneration compared to untreated controls ^[8]. These preclinical findings are internally consistent but are limited by species translation: rodent adipose biology and GH physiology differ meaningfully from humans.

Human evidence is more limited and ultimately inconclusive for the obesity indication. Phase IIa data suggested a meaningful weight-loss signal over 12 weeks ^[9], but the definitive 24-week Phase IIb trial in 536 subjects found no statistically significant weight loss at any concentration tested, leading to the termination of commercial development and rejection of obesity indications by both the FDA and Australian TGA ^[6][10]. Across six trials totalling 893 subjects, the safety and tolerability record was consistently excellent—no serious adverse events, no IGF-1 elevation, no glucose perturbation—but efficacy did not translate at the population level ^[3][6]. No human randomised trial has been published for cartilage repair, bone metabolism, or any other secondary indication ^[10]. Key evidence gaps include: absence of Phase III data for any indication, no long-term safety studies beyond the trial period, no published mechanistic human pharmacology studies, and limited head-to-head comparisons with approved anti-obesity agents.

Frequently asked questions

What is AOD-9604 and what is it a fragment of?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region (amino acids 176–191) of human growth hormone, with an added N-terminal tyrosine for stability. It was engineered to retain the fat-metabolising activity of GH while removing its growth-promoting and blood-sugar-altering effects. The name stands for 'Anti-Obesity Drug 9604'. It is a research compound and has not been approved as a drug by any major regulatory authority.

Is AOD-9604 approved by the FDA?

AOD-9604 does not hold FDA approval for any medical or therapeutic indication. As of April 2026, it is classified as an FDA Category 2 bulk drug substance, meaning compounding use is restricted pending further review. It does hold a separate GRAS (Generally Recognized As Safe) designation as a food ingredient, but this is a food-safety classification, not a drug approval, and does not authorise its use as a therapeutic agent.

Did AOD-9604 work in human clinical trials for weight loss?

Results were mixed across trials. An early Phase IIa trial showed approximately 1.8 kg more weight loss than placebo over 12 weeks. However, the larger, definitive Phase IIb trial—a 24-week study in 536 subjects—did not achieve statistically significant weight loss at any concentration tested, and both the FDA and the Australian TGA declined to approve an obesity indication. Commercial development was discontinued around 2007.

Does AOD-9604 raise IGF-1 or affect blood sugar?

Based on both animal and human study data, AOD-9604 does not appear to elevate plasma IGF-1 or disrupt glucose homeostasis. This distinguishes it from full-length growth hormone, which typically raises IGF-1 and can impair insulin sensitivity. Across six human trials enrolling 893 subjects, no clinically significant changes in IGF-1 or glucose parameters were recorded.

How does AOD-9604 differ from growth hormone (GH)?

Full-length GH acts through the GH receptor and downstream JAK2/STAT5 signalling, raising IGF-1, promoting tissue growth, and potentially worsening insulin resistance. AOD-9604 does not bind competitively to the GH receptor, does not elevate IGF-1, and does not cause hyperglycaemia in studied models. Its proposed mechanism involves beta-3 adrenergic receptor pathways and direct adipocyte lipolysis, making it a more targeted research tool for studying fat metabolism specifically.

Can AOD-9604 repair cartilage or help with osteoarthritis?

Preclinical evidence from rabbit osteoarthritis models suggests AOD-9604 may promote cartilage regeneration, particularly when combined with hyaluronic acid. In vitro data also indicate increased proteoglycan and collagen production in chondrocytes. However, no human randomised controlled trial examining AOD-9604 for osteoarthritis or cartilage repair has been published, so this remains a hypothesis-generating area of preclinical research only.

Is AOD-9604 the same thing as HGH Fragment 176-191?

The two terms are closely related but not identical. HGH Fragment 176-191 refers to the raw GH sequence at those amino acid positions. AOD-9604 is a modified version of that fragment with an additional N-terminal tyrosine residue added for molecular stability and biological activity. In practice, the terms are often used interchangeably in the research literature, but AOD-9604 specifically denotes the tyrosine-stabilised analogue developed by Metabolic Pharmaceuticals Ltd.

What was the safety record of AOD-9604 in human studies?

Across all six human clinical trials enrolling a combined 893 subjects, AOD-9604 demonstrated an exceptionally clean safety and tolerability profile: no treatment-related serious adverse events, no participant withdrawals attributed to the compound, no antibody formation, no allergic reactions, and no meaningful changes in IGF-1 or glucose levels were reported. Long-term safety beyond the study periods has not been characterised.

What is the regulatory status of AOD-9604 in Canada?

AOD-9604 does not hold a Notice of Compliance or Drug Identification Number from Health Canada for any therapeutic indication. As with most synthetic research peptides, it is not approved for human therapeutic use in Canada. It is available from Canadian suppliers solely as a research compound for in-vitro or preclinical laboratory investigation.

Why was AOD-9604 development stopped if early trials looked promising?

The compound showed encouraging signals in smaller early-phase human trials and robust effects in rodent models. However, the pivotal Phase IIb trial—designed with sufficient statistical power in 536 subjects—failed to demonstrate significant weight loss versus placebo at any concentration tested. Both the FDA and Australia's TGA declined obesity approval based on this outcome. The pharmaceutical company behind the development subsequently went into administration, ending the commercial development programme around 2007.

Glossary

Lipolysis

The enzymatic hydrolysis of stored triglycerides into free fatty acids and glycerol, releasing lipid energy stores from adipocyte cells.

Lipogenesis

The metabolic synthesis of fatty acids and triglycerides from non-fat precursors such as glucose or acetyl-CoA, representing the reverse process of lipolysis.

Beta-3 adrenergic receptor (β3-AR)

A G-protein-coupled receptor expressed predominantly in white and brown adipose tissue that, when activated, promotes lipolysis, thermogenesis, and fat oxidation.

IGF-1 (Insulin-like Growth Factor 1)

A hormone produced primarily in the liver in response to GH receptor activation; mediates many of GH's growth-promoting and anabolic effects, and its elevation is associated with diabetogenic risk.

Hormone-sensitive lipase (HSL)

The rate-limiting intracellular enzyme responsible for hydrolyzing stored triglycerides in adipocytes; its activation is a key step in catecholamine-stimulated lipolysis.

GRAS (Generally Recognized As Safe)

A U.S. FDA food-safety designation indicating that qualified experts have concluded a substance is safe for its intended use as a food ingredient, which is categorically distinct from drug approval.

Chondrocyte

The specialised cell type found in cartilage tissue that produces and maintains the extracellular matrix components—including collagen type II, aggrecan, and proteoglycans—required for cartilage structure and function.

Phase IIb clinical trial

A randomised controlled trial conducted in a larger patient population than earlier phases (typically several hundred participants) designed to rigorously assess whether a drug achieves its primary efficacy endpoint before advancing to Phase III.

References

1. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans — Journal of Endocrinology and Metabolism
2. Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice — Heffernan et al., Endocrinology 2001 — Endocrinology (Oxford Academic / PubMed PMID 11713213)
3. AOD-9604: A Growth Hormone C-Terminal Fragment With Human Trial Data but No Clear Path Forward — Superpower Research Guide (citing published trial literature)
4. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health — Journal of Endocrinology and Metabolism
5. Use of Growth Hormone Fragments — U.S. Patent 10,758,593 (Metabolic Pharmaceuticals Ltd) — United States Patent and Trademark Office
6. AOD 9604 — Research Guide & Fat Metabolism (citing Phase IIb PROOF study outcomes) — Peptide Library Research Reference
7. AOD 9604 Peptide: Research Into Fat Cell Metabolism and Lipolysis — Biotech Peptides Research Blog (citing Heffernan et al. 2001, PMID 11713213)
8. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model — Kwon DR et al., Ann Clin Lab Sci 2015;45(4):426-432 — Annals of Clinical and Laboratory Science (ResearchGate record)
9. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone — ResearchGate (peer-reviewed publication record)
10. AOD-9604 What the Research Actually Says: Evidence Review — TrimRx Evidence Review (citing Phase IIb and regulatory outcomes)
11. Generally Recognized as Safe (GRAS) — FDA Overview — U.S. Food and Drug Administration
12. AOD-9604: Mechanism, Effects & Research Studies — PeptPedia Research Reference
13. Therapeutic Potential of the β3-Adrenergic Receptor and Its Ligands in Cardiovascular Diseases (PMC12732782) — PubMed Central (peer-reviewed review article)